DBVT

NASDAQ 已收盘

DBV Technologies

9.42 USD
▼-0.26-2.69%
盘后 9.51 +0.96%
2026-11-19
市值
$571.97M
市盈率
—
EPS
-2.70
股息率
—
52 周区间
8.63 – 26.19
成交量
243.98K
Beta
-0.21
目标价
36.51
52W 低 8.6352W 高 26.19
价格走势

公司简介

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ...